Mesorectal Microbiome and Metabolome as a Prognostic Factor in Patients With Rectal Cancer (BIORECTUM)
Mesorectal Microbiome and Metabolome as a Prognostic Factor in Patients With Rectal Cancer and Analysis of it's Applicability in Neoadjuvant Treatment
The equilibrium of intestinal microorganisms is essential for health an imbalance has been associated with an increased risk in the development of different pathologies; including colorectal cancer.
Rectal cancer is the third most common neoplasm worldwide and the complete excision of the mesorectum is a major prognostic factor.
The identification of microorganisms in the adipose tissue that surrounds the small intestine in inflammatory diseases, together with bacterial alterations found in colonic mucosa and feces in patients with rectal cancer in comparison with healthy individuals indicates that microbiome alteration plays an essential role in pathogenesis.
The mesorectal microbiome in rectal cancer patients stills unknown and given its importance in the prognostic of the disease the goal of this study is to identify microbial profiles that allow predicting rectal cancer patients with a poor prognosis.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
The 5-year survival rate for patients with rectal cancer is 64%. Despite the development of personalized cancer treatments, the implantation of surgical approaches with more precise fields of vision and the current prognostic factors based on the quality of resection of the surgical specimen (intact margins and complete resection of the mesorectum), the long-term results for patients with rectal cancer remain grim.
Recently, it has been shown that dysfunctional fat tissue is characterized by tissue remodeling, grater lipids deposits and high adipokines secretion generates a pro inflammatory state, hypoxia and angiogenesis. These products generated by dysfunctional peritumoral adipose tissue create an ideal microenvironment for initiation and tumor progression.
The presence of microbiome in the mesentery of patients with colitis has confirmed the translocation of microorganisms from the intestine to adjacent tissues, together with the differences found in the bacterial composition in colonic mucosa and fecal samples between patients with rectal cancer and healthy individuals, and the prognosis value of the quality of mesorectum resection suggests that the microbiome present in lymph-fatty tissue in patients with rectal cancer may be a key element in mesorectum dysfunction, progression and dissemination of oncological disease.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Antoni Codina Cazador, MD, PhD
- Puhelinnumero: +34972940256
- Sähköposti: acodinac.girona.ics@gencat.cat
Opiskelupaikat
-
-
Girona
-
Girona, Girona, Espanja, 17007
- Rekrytointi
- Hospital Universitari Dr. Josep Trueta de Girona
-
Ottaa yhteyttä:
- Antoni Codina, MD, PhD
- Puhelinnumero: 972940256
- Sähköposti: acodinac.girona.ics@gencat.cat
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Patients with colorectal cancer that will undergo elective surgery
- Patients diagnosed with non-oncological disease with an indication for elective surgery.
- Age ≥ 18 years
- Histology proven adenocarcinoma or adenoma with or without chemotherapy or neoadjuvant radiochemotherapy
- Tumoral stage equal or grater than T1
- Attempt to R0 resection
- Signed informed consent by the patient and by the researcher
- Dietary Questionnaire completed
Exclusion Criteria:
- Colorectal tumor with different histology to adenocarcinoma or adenoma
- History of colorectal cancer surgery different to the local excision
- Patients with psychiatric illness, addiction or disorder with inability to understand informed consent
- Inability to read or understand any of the languages of the informed consent and questionnaires (Catalan, spanish)
- Another synchronous malignancy
- Emergency Surgery
- Any patient that medical characteristics present an individual risk raised to be included and complete the study
- Severe kidney or liver disease
- Systemic disease with inflammatory activity, such as rheumatoid arthritis, Crohn's disease, asthma, chronic infection (HIV,TBC).
- Pregnancy and lactation
- Severe disorder of eating behaviour
- Clinical symptoms and sings of infection in the previous month
- Antibiotic, antifungal and antiviral treatment for the last 3 months
- Anti-inflammatory chronic treatment
- Major psychiatric antecedents
- Excessive alcohol intake or drug abuse
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
Early-rectal cancer
The patients to be included in this group will be those with Stage I (initial tumor stage).
The tumors classified in stage I will be tumors in which the invasion of the submucosa and / or the invasion of the muscularis propria occur.
This group will include patients diagnosed preoperatively with tumor stage T1-T2 N0.
|
One stool sample will be taken at baseline for microbiota characterization
Characterization of tissue microbiota before and after surgery.
Characterization of tissue microbiota and dysfunction
Characterization of tissue microbiota and dysfunction
Characterization of tissue microbiota and dysfunction
Dietary assessment will be taken at baseline
|
|
Advanced-rectal cancer
The patients to be included in this group will be those with Stages II and III, that is, advanced tumors at the time of preoperative diagnosis.
Tumors included in this group invade the perirectal fat and / or the surface of the visceral peritoneum and / or invade or adhere to adjacent organs or structures.
In addition, any tumor stage with lymph nodes without distant metastases will be included in this group.
|
One stool sample will be taken at baseline for microbiota characterization
Characterization of tissue microbiota before and after surgery.
Characterization of tissue microbiota and dysfunction
Characterization of tissue microbiota and dysfunction
Characterization of tissue microbiota and dysfunction
Dietary assessment will be taken at baseline
|
|
Synchronous metastasis -rectal cancer
The patients to be included in this group will be those with Stage IV (disseminated tumor stage) in the initial study of the disease.
Patients with distant metastases in one organ or more than one organ will be included.
|
One stool sample will be taken at baseline for microbiota characterization
Characterization of tissue microbiota before and after surgery.
Characterization of tissue microbiota and dysfunction
Characterization of tissue microbiota and dysfunction
Characterization of tissue microbiota and dysfunction
Dietary assessment will be taken at baseline
|
|
Control group
Patients diagnosed with non-oncological disease
|
One stool sample will be taken at baseline for microbiota characterization
Characterization of tissue microbiota and dysfunction
Characterization of tissue microbiota and dysfunction
Dietary assessment will be taken at baseline
|
|
Patients diagnosed with colon cancer
Patients diagnosed with colon cancer who require elective surgery.
|
One stool sample will be taken at baseline for microbiota characterization
Characterization of tissue microbiota and dysfunction
Characterization of tissue microbiota and dysfunction
Dietary assessment will be taken at baseline
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Identification of mesorectal microbial and metabolomic biomarkers as prognostic factor for rectal cancer
Aikaikkuna: Up to 5 years after rectal cancer surgery
|
Correlation between mesorectal microbial and metabolomic signatures and survival
|
Up to 5 years after rectal cancer surgery
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Adipose tissue, fecal and rectal mucosa microbiome and metabolome characterisation
Aikaikkuna: Up to 1 month after rectal cancer surgery
|
Qualitative and quantitative analysis of the microbiome and metabolome of adipose tissue, feces, and rectal mucosa in patients with rectal cancer
|
Up to 1 month after rectal cancer surgery
|
|
Adipose tissue, fecal and rectal mucosa metabolomic dysfunctionality and its correlation with microbial dysbiosis
Aikaikkuna: Up to 1 month after rectal cancer surgery
|
Analysis of adipose tissue, fecal and rectal mucosa dysfunctionality tissue inflammation, angiogenesis and hypoxia and its correlation with microbial dysbiosis
|
Up to 1 month after rectal cancer surgery
|
|
Adipose tissue, fecal and rectal mucosa dysfunctionality and dysbiosis on tumor progression and response
Aikaikkuna: Up to 1 month after rectal cancer surgery
|
Correlation between adipose tissue, fecal and rectal mucosa dysfunction and response to neoadjuvant treatment
|
Up to 1 month after rectal cancer surgery
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat sivustoittain
- Neoplasmat
- Suoliston sairaudet
- Ruoansulatuskanavan kasvaimet
- Ruoansulatuskanavan kasvaimet
- Ruoansulatuskanavan sairaudet
- Ruoansulatuskanavan sairaudet
- Kolorektaaliset kasvaimet
- Suoliston kasvaimet
- Peräsuolen sairaudet
- Peräsuolen kasvaimet
- Terveydenhuollon laatu, saatavuus ja arviointi
- Tutkintatekniikat
- Epidemiologiset menetelmät
- Tiedonkeruu
- Terveydenhuollon arviointimekanismit
- Terveydenhuollon laatu
- Kansanterveys
- Ympäristö ja kansanterveys
- Epidemiologiset mittaukset
- Ravitsemusarviointi
Muut tutkimustunnusnumerot
- 2021.028
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .